Antithrombotics: In A Crowded Field Of Candidates, Does Being First Matter?

The cresting wave of novel antithrombotic NDAs could mean 2010 will be a difficult year for FDA's Division of Cardiovascular and Renal Products, as the products have massive applications and tricky risk-benefit evaluations.